Ardelyx (ARDX) is back in focus after recent trading, with the stock closing at $5.67 and showing mixed short term performance, including a decline over the past month and a gain over the past 3 months.

Looking beyond the latest move, Ardelyx’s share price return is down over the past month but slightly up over the past quarter, while its 1 year total shareholder return is strongly positive. This suggests earlier optimism is being reassessed rather than completely reversed.

If Ardelyx’s recent swings have you thinking about other opportunities in healthcare, it could be a good time to scan for promising healthcare AI stocks using the 40 healthcare AI stocks.

With Ardelyx stock trading at a steep discount to the average analyst price target and showing strong 1 year gains, the key question is whether this gap signals a fresh entry opportunity or if the market is already pricing in future growth.

Most Popular Narrative: 65.3% Undervalued

Compared with Ardelyx stock at $5.67, the most widely followed narrative points to a fair value near $16.33, built on ambitious revenue and profitability assumptions using a 7.34% discount rate.

The rising prevalence of chronic kidney disease (CKD) and gastrointestinal disorders driven by an aging population continues to expand Ardelyx's core addressable markets, supporting sustained long-term demand for IBSRELA and XPHOZAH and driving future revenue growth. Recent and ongoing improvements in market access, prescription pull-through, and expansion of the sales force are boosting prescriber breadth and depth, contributing to accelerating product adoption and positioning the company to achieve strong topline growth and improved gross margins as fixed costs are leveraged.

Want the full playbook behind that $16.33 figure? It leans heavily on fast compounding revenue, sharply higher margins, and a future earnings profile very different to today.

Result: Fair Value of $16.33 (UNDERVALUED)

However, Ardelyx’s story also hinges on risks, including its heavy reliance on IBSRELA and XPHOZAH, as well as ongoing uncertainty around XPHOZAH’s Medicare reimbursement access.

Next Steps

Mixed signals around Ardelyx can make it hard to lean fully bullish or cautious. It may help to weigh the potential upside against the concerns and form your own view using the 4 key rewards and 1 important warning sign.

Looking for more investment ideas beyond Ardelyx stock?

Before moving on, give yourself the advantage of a broader watchlist by checking other opportunities that could balance your Ardelyx view and sharpen your overall portfolio thinking.

• Spot potential mispriced opportunities early by scanning the 44 high quality undervalued stocks that may warrant a closer look alongside Ardelyx.
• Strengthen your downside protection by reviewing the 67 resilient stocks with low risk scores that pair more resilient profiles with measured growth potential.
• Broaden your opportunity set by searching the screener containing 20 high quality undiscovered gems that many investors might be overlooking today.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.